Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20900599 | 0.97 | CYP1A2 (0.42) | CYP1A2ALOX5OPRM1OPRD1OPRK1 | |
| SCHEMBL16559079 | 0.97 | CYP1A2 (0.42) | CYP1A2ALOX5OPRM1OPRD1OPRK1 | |
| SCHEMBL12018411 | 0.97 | CYP1A2 (0.42) | CYP1A2ALOX5OPRM1OPRD1OPRK1 | |
| SCHEMBL9256109 | 0.94 | OPRM1 (0.41) | CYP1A2ALOX5OPRM1OPRD1OPRK1 | |
| SCHEMBL26714515 | 0.92 | CYP1A2 (0.42) | CYP1A2ALOX5OPRM1OPRD1OPRK1 | |
| SCHEMBL23482120 | 0.89 | OPRM1 (0.41) | CYP1A2ALOX5OPRM1OPRD1OPRK1 | |
| SCHEMBL14183042 | 0.88 | — | — | |
| SCHEMBL16577641 | 0.87 | CYP1A2 (0.39) | CYP1A2ALOX5OPRM1OPRD1OPRK1 | |
| SCHEMBL18602491 | 0.86 | OPRM1 (0.39) | CYP1A2ALOX5OPRM1OPRD1OPRK1 | |
| SCHEMBL16577647 | 0.85 | CYP1A2 (0.38) | CYP1A2ALOX5OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000078826-A1 | CATALYSTS | BOREALIS TECHNOLOGY OY (FI) | 2000-12-28 | — | — | WO | claimed |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2018045084-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| EP-2427425-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2710005-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140303161-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303190-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8580812-B2 | Heteroaryl amide analogues as P2X7 antagonists | H. LUNDBECK A/S (DK) | 2013-11-12 | — | — | US | disclosed |
| US-20130172549-A1 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-8431593-B2 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| WO-2000078826-A1 | CATALYSTS | BOREALIS TECHNOLOGY OY (FI) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | CYP1A2 3432/4885ALOX5 2104/4885OPRM1 3011/4885 |
| US-20140303161-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | CYP1A2 3432/4885ALOX5 2104/4885OPRM1 3011/4885 |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | CYP1A2 3432/4885ALOX5 2104/4885OPRM1 3011/4885 |
| US-20140303190-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | CYP1A2 3432/4885ALOX5 2104/4885OPRM1 3011/4885 |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | CYP1A2 1052/4885ALOX5 600/4885OPRM1 1084/4885 |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | CYP1A2 3432/4885ALOX5 2104/4885OPRM1 3011/4885 |
| US-20130172549-A1 | Heteroaryl amide derivatives | HCAR2, PIGS, GPR52 | CYP1A2 398/4885ALOX5 1363/4885OPRM1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.